STRATA CRITICAL MEDICAL INC (SRTA) Fundamental Analysis & Valuation

NASDAQ:SRTA • US0926671043

Current stock price

4.115 USD
-0.02 (-0.6%)
Last:

This SRTA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. SRTA Profitability Analysis

1.1 Basic Checks

  • SRTA had negative earnings in the past year.
  • SRTA had a negative operating cash flow in the past year.
  • In the past 5 years SRTA reported 4 times negative net income.
  • SRTA had a negative operating cash flow in each of the past 5 years.
SRTA Yearly Net Income VS EBIT VS OCF VS FCFSRTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M -40M

1.2 Ratios

Industry RankSector Rank
ROA 11.93%
ROE 14.13%
ROIC N/A
ROA(3y)-5.63%
ROA(5y)-7.4%
ROE(3y)-7.13%
ROE(5y)-9.02%
ROIC(3y)N/A
ROIC(5y)N/A
SRTA Yearly ROA, ROE, ROICSRTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150

1.3 Margins

  • In the last couple of years the Gross Margin of SRTA has grown nicely.
Industry RankSector Rank
OM N/A
PM (TTM) 17.48%
GM 23.78%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.75%
GM growth 5YN/A
SRTA Yearly Profit, Operating, Gross MarginsSRTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40 -60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. SRTA Health Analysis

2.1 Basic Checks

  • SRTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SRTA Yearly Shares OutstandingSRTA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
SRTA Yearly Total Debt VS Total AssetsSRTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • SRTA has an Altman-Z score of 4.10. This indicates that SRTA is financially healthy and has little risk of bankruptcy at the moment.
  • SRTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.1
ROIC/WACCN/A
WACCN/A
SRTA Yearly LT Debt VS Equity VS FCFSRTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 100M 200M

2.3 Liquidity

  • A Current Ratio of 4.36 indicates that SRTA has no problem at all paying its short term obligations.
  • SRTA has a Quick Ratio of 4.36. This indicates that SRTA is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 4.36
Quick Ratio 4.36
SRTA Yearly Current Assets VS Current LiabilitesSRTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. SRTA Growth Analysis

3.1 Past

  • SRTA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 29.73%, which is quite impressive.
  • Looking at the last year, SRTA shows a decrease in Revenue. The Revenue has decreased by -3.02% in the last year.
  • The Revenue has been growing by 10.50% on average over the past years. This is quite good.
EPS 1Y (TTM)29.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.69%
Revenue 1Y (TTM)-3.02%
Revenue growth 3Y10.5%
Revenue growth 5YN/A
Sales Q2Q%22.87%

3.2 Future

  • Based on estimates for the next years, SRTA will show a very strong growth in Earnings Per Share. The EPS will grow by 37.20% on average per year.
  • Based on estimates for the next years, SRTA will show a quite strong growth in Revenue. The Revenue will grow by 17.22% on average per year.
EPS Next Y78.42%
EPS Next 2Y37.2%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year26.25%
Revenue Next 2Y17.22%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SRTA Yearly Revenue VS EstimatesSRTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M 200M 250M
SRTA Yearly EPS VS EstimatesSRTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6

More info and screens

Find the best growth stocksShow best growing peers

1

4. SRTA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SRTA. In the last year negative earnings were reported.
  • Also next year SRTA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SRTA Price Earnings VS Forward Price EarningsSRTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40 -60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SRTA Per share dataSRTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

  • SRTA's earnings are expected to grow with 37.20% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.2%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SRTA Dividend Analysis

5.1 Amount

  • SRTA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SRTA Fundamentals: All Metrics, Ratios and Statistics

STRATA CRITICAL MEDICAL INC

NASDAQ:SRTA (3/30/2026, 3:03:25 PM)

4.115

-0.02 (-0.6%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)03-03
Earnings (Next)05-11
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner Change6.93%
Market Cap0
Revenue(TTM)241.19M
Net Income(TTM)39.98M
Analysts85
Price Target9.82 (138.64%)
Short Float %N/A
Short Ratio6.22
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-53.74%
Min EPS beat(2)-96.08%
Max EPS beat(2)-11.41%
EPS beat(4)1
Avg EPS beat(4)-16.86%
Min EPS beat(4)-96.08%
Max EPS beat(4)64.99%
EPS beat(8)3
Avg EPS beat(8)-46.19%
EPS beat(12)5
Avg EPS beat(12)-23.19%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)9.08%
Min Revenue beat(2)8.32%
Max Revenue beat(2)9.84%
Revenue beat(4)4
Avg Revenue beat(4)7.53%
Min Revenue beat(4)4.23%
Max Revenue beat(4)9.84%
Revenue beat(8)6
Avg Revenue beat(8)4.07%
Revenue beat(12)10
Avg Revenue beat(12)5.21%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)1.29%
Revenue NY rev (3m)1.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.48
P/FCF N/A
P/OCF N/A
P/B 1.19
P/tB 2.28
EV/EBITDA N/A
EPS(TTM)-0.26
EYN/A
EPS(NY)-0.06
Fwd EYN/A
FCF(TTM)-0.69
FCFYN/A
OCF(TTM)-0.52
OCFYN/A
SpS2.79
BVpS3.45
TBVpS1.8
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 11.93%
ROE 14.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 17.48%
GM 23.78%
FCFM N/A
ROA(3y)-5.63%
ROA(5y)-7.4%
ROE(3y)-7.13%
ROE(5y)-9.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.75%
GM growth 5YN/A
F-Score3
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 208.79%
Cap/Sales 6.12%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.36
Quick Ratio 4.36
Altman-Z 4.1
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.69%
EPS Next Y78.42%
EPS Next 2Y37.2%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-3.02%
Revenue growth 3Y10.5%
Revenue growth 5YN/A
Sales Q2Q%22.87%
Revenue Next Year26.25%
Revenue Next 2Y17.22%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y56.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year369.58%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-48.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-323.73%
OCF growth 3YN/A
OCF growth 5YN/A

STRATA CRITICAL MEDICAL INC / SRTA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of STRATA CRITICAL MEDICAL INC (SRTA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to SRTA.


Can you provide the valuation status for STRATA CRITICAL MEDICAL INC?

ChartMill assigns a valuation rating of 1 / 10 to STRATA CRITICAL MEDICAL INC (SRTA). This can be considered as Overvalued.


What is the profitability of SRTA stock?

STRATA CRITICAL MEDICAL INC (SRTA) has a profitability rating of 1 / 10.


What is the financial health of STRATA CRITICAL MEDICAL INC (SRTA) stock?

The financial health rating of STRATA CRITICAL MEDICAL INC (SRTA) is 6 / 10.


What is the expected EPS growth for STRATA CRITICAL MEDICAL INC (SRTA) stock?

The Earnings per Share (EPS) of STRATA CRITICAL MEDICAL INC (SRTA) is expected to grow by 78.42% in the next year.